Humacyte, Inc.
HUMA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001818382
In the last 90 days, Humacyte, Inc. insiders filed 3 open-market purchases and 0 sales; 164 institutions reported holding it in 13F filings for Q2 2026, worth $57.3M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $30.4K in total
- 3
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +7 vs. previous quarter
- 164
- 13F valueReported value at the end of Q2 2026
- $57.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding HUMA, Q2 2026
No superinvestor reported holding HUMA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Humacyte, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 15, 2026 (view filing)4:05 PM ET | Sep 14 | 1 day | Jones Keith AnthonyDirector | PPurchase | +10.0K | $0.562 | +$5.62K | +25.0%50.0K after | |
| Aug 21, 2026 (view filing)4:05 PM ET | Aug 20 | 1 day | Jones Keith AnthonyDirector | PPurchase | +10.0K | $0.693 | +$6.93K | +33.3%40.0K after | |
| Aug 19, 2026 (view filing)4:00 PM ET | Aug 17 | 2 days | Jones Keith AnthonyDirector | PPurchase | +30.0K | $0.594 | +$17.8K | New position30.0K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Parikh Shamik JChief Medical Officer | SSale | −45.9K | $0.90 | −$41.3K | −14.4%272.7K after | 10b5-1 |
| May 20, 2026 (view filing) | May 18 | 2 days | Sander Dale A.CFO and Chief Corp. Dev. Off | SSale | −45.9K | $0.90 | −$41.3K | −14.7%267.2K after | 10b5-1 |
| May 20, 2026 (view filing) | May 18 | 2 days | Constantino Michael T.Director | PPurchase | +11.0K | $0.89 | +$9.79K | +33.4%44.0K after | |
| May 20, 2026 (view filing) | May 19 | 1 day | Sebelius KathleenDirector | PPurchase | +56.8K | $0.88 | +$50.0K | +62.3%148.0K after | |
| Aug 20, 2025 (view filing) | Aug 18-20 | 2 days | Dougan Brady WDirector | SSale | −2.24M | $1.67 | −$3.73M | −100.0%0 after | 3 lotsDuplicate filing |
| Aug 20, 2025 (view filing) | Aug 18-20 | 2 days | Niklason Laura EPresident, CEO and Director | SSale | −2.24M | $1.67 | −$3.73M | −100.0%0 after | 3 lots |
| Apr 15, 2025 (view filing) | Apr 14 | 1 day | Scheessele William JohnChief Commercial Officer | PPurchase | +6.49K | $1.54 | +$10.0K | +41.8%22.0K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Humacyte, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Antipodes Partners Ltd | 10,103,647 | $7.88M | 0.14% | +4,379,897+76.5% | Added |
| Vanguard Capital Management LLC | 10,107,679 | $7.88M | 0.00% | +2,949,517+41.2% | Added |
| Alyeska Investment Group, L.P. | 6,022,925 | $4.70M | 0.01% | +6,022,925 | New |
| Davidson Kempner Capital Management LP | 5,000,000 | $3.90M | 0.06% | +5,000,000 | New |
| BlackRock, Inc. | 4,839,929 | $3.78M | 0.00% | −7,477,026−60.7% | Reduced |
| Great Point Partners LLC | 3,750,000 | $2.93M | 0.69% | 00.0% | Unchanged |
| UBS Group AG | 2,843,493 | $2.22M | 0.00% | +61,423+2.2% | Added |
| AQR Capital Management LLC | 2,597,134 | $2.03M | 0.00% | +672,443+34.9% | Added |
| Geode Capital Management, LLC | 2,185,225 | $1.71M | 0.00% | −1,472,883−40.3% | Reduced |
| Millennium Management LLC | 1,909,049 | $1.49M | 0.00% | +1,800,895+1,665.1% | Added |